中国伤残医学
中國傷殘醫學
중국상잔의학
CHINESE JOURNAL OF TRAUMA AND DISABILITY MEDICINE
2014年
3期
18-19
,共2页
噻托溴铵%重度慢性阻塞性肺疾病%肺功能%不良反应
噻託溴銨%重度慢性阻塞性肺疾病%肺功能%不良反應
새탁추안%중도만성조새성폐질병%폐공능%불량반응
Tiotropium Bromide%Chronic obstructive pulmonary disease%Adverse reactions
目的：探讨噻托溴铵辅助治疗慢性阻塞性肺疾病的疗效。方法：慢性阻塞性肺疾病患者80例，随机分为治疗组与对照组，各40例。对照组采用常规综合疗法，治疗组在此基础上给予噻托溴铵辅助治疗。结果：治疗后治疗组的FEV1、FEV1/FVC与PEF值明显高于对照组，差异有统计学意义（ P＜0．05）。对照组出现口干1例，尿潴留1例；治疗组出现口干2例，尿潴留1例。2组不良反应对比差异无统计学意义（P＞0．05）。结论：吸入噻托溴铵辅助治疗慢性阻塞性肺病患者能有效改善肺功能，不良反应少，值得临床推广应用。
目的：探討噻託溴銨輔助治療慢性阻塞性肺疾病的療效。方法：慢性阻塞性肺疾病患者80例，隨機分為治療組與對照組，各40例。對照組採用常規綜閤療法，治療組在此基礎上給予噻託溴銨輔助治療。結果：治療後治療組的FEV1、FEV1/FVC與PEF值明顯高于對照組，差異有統計學意義（ P＜0．05）。對照組齣現口榦1例，尿潴留1例；治療組齣現口榦2例，尿潴留1例。2組不良反應對比差異無統計學意義（P＞0．05）。結論：吸入噻託溴銨輔助治療慢性阻塞性肺病患者能有效改善肺功能，不良反應少，值得臨床推廣應用。
목적：탐토새탁추안보조치료만성조새성폐질병적료효。방법：만성조새성폐질병환자80례，수궤분위치료조여대조조，각40례。대조조채용상규종합요법，치료조재차기출상급여새탁추안보조치료。결과：치료후치료조적FEV1、FEV1/FVC여PEF치명현고우대조조，차이유통계학의의（ P＜0．05）。대조조출현구간1례，뇨저류1례；치료조출현구간2례，뇨저류1례。2조불량반응대비차이무통계학의의（P＞0．05）。결론：흡입새탁추안보조치료만성조새성폐병환자능유효개선폐공능，불량반응소，치득림상추엄응용。
Objective:To explore the effect of Tiotropium Bromide in adjuvant treatment of chronic obstructive pulmonary disease . Methods:80 samples were randomly divided into the treatment group and the control group of 40 cases respectively .The control group was treated with routine treatment and the treatment group was added to Tiotropium Bromide .Results:The FEV1、FEV1/FVC、and PEF of the treatment group was higher than the control group after treatment , and the difference was statistically significant (P<0.05).There were 1 patient with xerostomia and 1 patient with uroschesis in the control group ,and 2patients with xerostomia and 1 patient with uroschesis in the treatment group .It was no statistically significant difference ( P>0.05 ) .Con clusion:It is worth to populate and apply that Tiotropium Bromide in adjuvant treatment of chronic obstructive pulmonary disease may be useful and safe .
